Q: Why have some regions been harder to eliminate?

LF elimination has been more challenging in: Sub-Saharan Africa (large populations requiring treatment; health system challenges; co-endemicity with loiasis — causing severe adverse events if given ivermectin); South Asia (large populations, urban slums with Culex breeding in drains); areas of conflict; and where treatment is refused or MDA coverage is incomplete (<65% coverage breaks transmission). Climate change may expand Culex range, threatening new areas.

Q: How does stigma affect LF?

LF stigma is profound and represents one of the most devastating consequences: people with visible lymphoedema or hydrocele face social exclusion, marriage refusal, loss of employment and psychological devastation. In many affected communities, elephantiasis is attributed to witchcraft or moral failing — deepening stigma. Women with LF of the genitalia face particularly severe social consequences. Reducing LF stigma is as important as preventing new infections — requiring community education alongside medical treatment.

Q: What drugs are donated for LF MDA?

Two major pharmaceutical donations support GPELF: Merck & Co. donates ivermectin (Mectizan) for LF MDA where co-endemic with onchocerciasis; GlaxoSmithKline (GSK) donates albendazole (400mg) for all LF MDA globally — the largest drug donation in history, delivering over 6 billion tablets. Eisai donates DEC for LF elimination in some settings. These donations have enabled LF MDA to be largely free to endemic countries.

Q: How does GMJ News cover lymphatic filariasis?

GMJ News covers WHO GPELF elimination progress, MDA coverage data, morbidity management, triple drug therapy evidence and the 2030 elimination target. LF is part of the GMJ's NTD coverage — reflecting PHIG's global health and tropical medicine agenda.

Question 1

What is lymphatic filariasis?

Accepted Answer

Lymphatic filariasis (LF) is caused by filarial nematode parasites (Wuchereria bancrofti — 90%; Brugia malayi; Brugia timori) transmitted by mosquitoes. Adult worms live in the lymphatic vessels, causing progressive lymphatic damage. The condition causes grotesque, disfiguring swellings: lymphoedema (enormously enlarged limbs — "elephantiasis") and hydrocele (scrotal swelling). LF is the second leading infectious cause of disability globally after mental illness, affecting 36 million with chronic disease.

Question 2

How is LF transmitted?

Accepted Answer

LF is transmitted exclusively by mosquitoes: Culex mosquitoes (W. bancrofti in most of the world); Anopheles (W. bancrofti in Africa); Mansonia and Anopheles (B. malayi). Infected mosquitoes deposit infective larvae (L3) on the skin when feeding. Larvae enter through the bite wound, migrate to the lymphatics, mature to adult worms over 12 months, and produce microfilariae that circulate in the blood at night (nocturnal periodicity — matching mosquito feeding times).

Question 3

What is elephantiasis?

Accepted Answer

Elephantiasis (gross lymphoedema) is the most visible manifestation of LF — caused by repeated inflammatory episodes (acute adenolymphangitis, ADL) damaging the lymphatic vessels and causing progressive lymph accumulation in limbs. Legs, arms, breasts and genitalia may be enormously enlarged, with thick, hardened, fissured skin. It causes profound disability, social stigma and poverty (inability to work). It is NOT caused by bacteria (ADL is caused by entry of bacteria through broken skin in damaged lymphatics).

Question 4

Is there treatment for people already disabled by LF?

Accepted Answer

MDA treats active infection and prevents new cases — but does not reverse established lymphoedema or hydrocele. For lymphoedema: meticulous skin hygiene (washing, moisturising, antifungal treatment of skin folds) combined with exercises and elevation dramatically reduces ADL attacks and slows progression. For hydrocele: surgical repair (hydrocelectomy) is curative. WHO's morbidity management and disability prevention (MMDP) programme provides these services alongside MDA.

Question 5

What is the MDA strategy?

Accepted Answer

Mass drug administration (MDA) — distributing antifilarial drugs to the entire at-risk population annually for 4-6+ years — kills microfilariae and adult worms, breaking transmission. Standard regimens: ivermectin + albendazole (where onchocerciasis is co-endemic); DEC + albendazole (elsewhere); or triple therapy IDA (ivermectin + DEC + albendazole) — faster MDA rounds. Achieved elimination in 17 countries including China, Japan, Korea, Maldives, Sri Lanka, Cambodia and many Pacific island nations.

Question 6

How does the LF elimination programme work?

Accepted Answer

GPELF (Global Programme to Eliminate Lymphatic Filariasis): (1) Mapping — identifying endemic areas. (2) MDA — annual treatment of all eligible people for 4-6 years. (3) Surveillance — monitoring microfilaraemia and antigen prevalence to confirm interruption of transmission. (4) Verification — independent WHO validation of elimination (<1% antigen prevalence in children 6-7 years). (5) Post-MDA surveillance — monitoring for recrudescence.

Question 7

Why have some regions been harder to eliminate?

Accepted Answer

LF elimination has been more challenging in: Sub-Saharan Africa (large populations requiring treatment; health system challenges; co-endemicity with loiasis — causing severe adverse events if given ivermectin); South Asia (large populations, urban slums with Culex breeding in drains); areas of conflict; and where treatment is refused or MDA coverage is incomplete (<65% coverage breaks transmission). Climate change may expand Culex range, threatening new areas.

Question 8

How does stigma affect LF?

Accepted Answer

LF stigma is profound and represents one of the most devastating consequences: people with visible lymphoedema or hydrocele face social exclusion, marriage refusal, loss of employment and psychological devastation. In many affected communities, elephantiasis is attributed to witchcraft or moral failing — deepening stigma. Women with LF of the genitalia face particularly severe social consequences. Reducing LF stigma is as important as preventing new infections — requiring community education alongside medical treatment.

Question 9

What drugs are donated for LF MDA?

Accepted Answer

Two major pharmaceutical donations support GPELF: Merck & Co. donates ivermectin (Mectizan) for LF MDA where co-endemic with onchocerciasis; GlaxoSmithKline (GSK) donates albendazole (400mg) for all LF MDA globally — the largest drug donation in history, delivering over 6 billion tablets. Eisai donates DEC for LF elimination in some settings. These donations have enabled LF MDA to be largely free to endemic countries.

Question 10

How does GMJ News cover lymphatic filariasis?

Accepted Answer

GMJ News covers WHO GPELF elimination progress, MDA coverage data, morbidity management, triple drug therapy evidence and the 2030 elimination target. LF is part of the GMJ's NTD coverage — reflecting PHIG's global health and tropical medicine agenda.

GMJ News

Lymphatic Filariasis

Key messages

Key statistics

Glossary of key terms

Latest GMJ coverage

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Company